Seeking Alpha

C.R. Jackson

 
View as an RSS Feed
View C.R. Jackson's Articles BY TICKER:
  • Volatile Versartis May Have Significant Upside
    Thu, Sep. 4 VSAR Comment!

    Summary

    • In June 2014, Versartis achieved a major corporate milestone with positive Phase 2a clinical results for VRS-317, confirming its potential to provide a new, long-acting growth hormone therapy.
    • Researchers also found that VRS-317 was safe and well-tolerated in the patient population tested.
    • The global market for Human Growth Hormone drugs is forecast to reach $4.7 billion by 2018.
  • These 2 Stocks Could Be Winners Because Plenty Of People Want To Look Younger
    Fri, Aug. 22 KYTH, RVNC 1 Comment

    Summary

    • Both Kythera Biopharmaceuticals and Revance Therapeutics are developing first in class drug candidates that have significant potential in the $10 billion cosmetic procedure market.
    • Both of these California-based companies are developing Phase 3 product candidates that tested extremely well in earlier trials.
    • Kythera and Revance anticipate having major catalysts that could substantially increase their stock price within the next nine months.
  • Why Have Revance Therapeutics Shares More Than Doubled Since The February IPO?
    Wed, Mar. 19 RVNC 1 Comment

    Summary

    • Injectable Botulinum toxin treatments are the most popular cosmetic procedure in the United States and the rest of the world.
    • A topical Botulinum toxin treatment could overcome consumer concerns about injectable Botulinum toxin, representing a potential billion dollar market opportunity.
    • Revance’s TransMTS technology could deliver other molecules across the skin that currently require injections.
    • Since its initial public offering (IPO) on February 6, 2014, Revance Therapeutics has more than doubled.
  • TetraLogic Pharmaceuticals And The Chatter About A Cure For Cancer
    Fri, Jan. 31 TLOG 6 Comments
  • Biopharma Bottomfishing: Are Any Of These 3 Stocks Under $9 A Good Catch?
    Tue, Jan. 28 LXRX, SNSS, VVUS 1 Comment
  • Evoke Pharma Moves Full Speed Ahead
    Sun, Jan. 26 EVOK 1 Comment
  • Five Prime Therapeutics: A Small Cap With A Big Protein Therapeutic Platform
    Fri, Jan. 10 FPRX 1 Comment
  • Tetraphase Pharmaceuticals: A Small Cap With Big Potential
       • Fri, Jan. 3 TTPH 1 Comment
  • NuPathe Takes Investors Down A Bumpy Road
       • Dec. 11, 2013 TEVA 8 Comments
  • Does Conatus Pharmaceuticals Have A Winner With Emricasan?
    Sep. 25, 2013 CNAT Comment!
  • Is Biodel A Buy Or Sell?
    Sep. 19, 2013 BIOD 17 Comments
  • How High Will Bluebird Bio Fly?
    Editors' Pick • Sep. 12, 2013 BLUE 4 Comments
  • Does Esperion Therapeutics Have A Blockbuster With ETC-1002?
       • Sep. 9, 2013 ESPR 1 Comment
  • Why Is BioCryst Pharmaceuticals At 52 Week High Levels?
       • Aug. 4, 2013 BCRX 5 Comments
  • Innovative KaloBios Pharmacuticals Could Be A Lucrative Buy
    Editors' Pick • Aug. 2, 2013 KBIO Comment!
  • Will Coronado Biosciences Revolutionize Medicine?
       • Jul. 8, 2013 CNDO 6 Comments
  • What Is On The Horizon For XOMA?
       • Jul. 1, 2013 XOMA Comment!
  • Will Big Changes At Apricus Biosciences Make It A Winning Stock?
    Jul. 1, 2013 APRI 24 Comments
  • Near A 52-Week Low, Is Ventrus Biosciences A Good Buy?
       • Jun. 27, 2013 VTUS 3 Comments
  • Can Cempra Beat The Superbugs?
       • Jun. 17, 2013 CEMP 2 Comments
  • Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?
       • Jun. 13, 2013 OGXI 1 Comment
  • Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High?
    Editors' Pick • Jun. 10, 2013 NLNK 2 Comments
  • Avanir Pharmaceuticals Builds A Pipeline In A Pill
    Jun. 3, 2013 AVNR 11 Comments
  • 3 Innovative Biotech Companies With Promising Cancer Therapies
    May. 29, 2013 ARIA, EXEL, MACK 1 Comment
  • Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company?
    May. 16, 2013 ARRY 1 Comment
  • Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
    May. 12, 2013 ARRY 4 Comments
  • Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
    May. 12, 2013 ARRY 2 Comments
  • Is It Time To Give Up On Dendreon?
    Editors' Pick • May. 7, 2013 DNDN 27 Comments
  • Why Did Pain Therapeutics Increase Over 25%?
    Editors' Pick • May. 2, 2013 PTIE 36 Comments
  • Questcor Pharmaceuticals: How Can Such A Profitable Company Be So Risky?
    Editors' Pick • Apr. 25, 2013 QCOR 46 Comments
  • Why Did Vanda Pharmaceuticals Hit A 52-Week High?
    Apr. 19, 2013 VNDA 5 Comments
  • 2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
    Apr. 17, 2013 CORT, CYTK 6 Comments